Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1653087 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $1.52Day +0.00%Mkt cap $169M1Y −5.6%Off 52W high −55.3%Vol (1Y) 103.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,875 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest5.1% of sh out |
| Days to cover10.2d |
| 13F net flow (QoQ)+2.23% |
| Top-10 13F concentration51.1% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$18.4M |
| Earnings (TTM)-$125.4M |
| ROE−181.6% |
| Net margin−679.2% |
| ROIC−318.7% |
| Debt / equity0.30× |
| Sales growth 3Y−46.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−2.6% |
| 1Y−5.6% |
| 3Y−77.8% |
| 5Y−93.7% |
| Since incept. (ann.)−28.2% |
Total return through 2026-07-29 · series begins 2019-02-07. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)103.3% |
| Ann. volatility (3Y)91.4% |
| Sharpe (1Y)0.41 |
| Sharpe (3Y)−0.05 |
| Max drawdown (1Y)−65.7% |
| Max drawdown (3Y)−89.7% |
| Beta (3Y vs SPY)1.17 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 10.0M | $22M | 9.01% | +0.0% |
| BlackRock, Inc. | 7.7M | $17M | 6.97% | +8.3% |
| ACADIAN ASSET MANAGEMENT LLC | 4.0M | $9M | 3.64% | +17.3% |
| Foresite Capital Management IV, LLC | 3.9M | $8M | 3.50% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7M | $8M | 3.31% | new |
| Merck & Co., Inc. | 3.5M | $8M | 3.19% | +0.0% |
| D. E. Shaw & Co., Inc. | 3.3M | $7M | 3.00% | +40.9% |
| 683 Capital Management, LLC | 3.2M | $7M | 2.88% | −4.5% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.21 | — | $1.0M | −71.7% |
| 2025-12-31 | 2026-02-25 | — | — | $6.2M | −88.5% |
| 2025-09-30 | 2025-11-06 | −$0.34 | — | $3.3M | −78.8% |
| 2025-06-30 | 2025-08-07 | −$0.30 | — | $7.9M | −47.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
